CTLA4 and melanoma: For instance, immunotherapeutic approaches such as administration of Anti-PD1 (nivolumab, pembrolizumab) alone, or the combination of anti-PD1 with anti-cytotoxic T lymphocyte-associated protein 4 (CTLA4) ipilimumab has raised the survival of patients who suffer from advanced stages of melanoma (6).